AbCellera Biologics Inc. (ABCL) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
19/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinABCL / S&P 124.93% / 15.20% |
WinABCL / S&P 101.28% / 15.00% |
LoseABCL / S&P -1.82% / 50.40% |
| 2026-Q12/3 |
WinABCL / S&P 2.05% / -4.33% |
WinABCL / S&P 242.66% / 11.30% |
LoseABCL / S&P -14.29% / 27.70% |
| 2025-Q41/3 |
LoseABCL / S&P -32.01% / 2.65% |
WinABCL / S&P 160.55% / 9.00% |
LoseABCL / S&P -10.91% / 13.40% |
| 2025-Q32/3 |
WinABCL / S&P 46.65% / 8.12% |
WinABCL / S&P 7.16% / 4.61% |
LoseABCL / S&P -6.56% / 13.45% |
| 2025-Q21/3 |
WinABCL / S&P 53.81% / 10.94% |
LoseABCL / S&P -0.54% / 4.83% |
LoseABCL / S&P 1.85% / 10.63% |
| 2025-Q10/3 |
LoseABCL / S&P -23.89% / -4.27% |
LoseABCL / S&P -35.41% / 4.98% |
LoseABCL / S&P 7.69% / 10.57% |
| 2024-Q41/3 |
WinABCL / S&P 12.69% / 2.41% |
LoseABCL / S&P -24.17% / 5.25% |
LoseABCL / S&P 5.77% / 6.15% |
| 2024-Q31/3 |
LoseABCL / S&P -12.16% / 5.89% |
LoseABCL / S&P -34.59% / 5.89% |
WinABCL / S&P 35.56% / 6.11% |
| 2024-Q21/3 |
LoseABCL / S&P -34.66% / 4.28% |
LoseABCL / S&P -77.23% / 5.38% |
WinABCL / S&P 100.00% / 5.12% |
| 2024-Q11/3 |
LoseABCL / S&P -20.67% / 10.56% |
LoseABCL / S&P -80.23% / 5.71% |
WinABCL / S&P 188.89% / 5.59% |
| 2023-Q41/3 |
WinABCL / S&P 24.13% / 11.69% |
LoseABCL / S&P -92.17% / 6.81% |
LoseABCL / S&P -204.00% / 7.78% |
| 2023-Q30/3 |
LoseABCL / S&P -28.79% / -3.27% |
LoseABCL / S&P -91.65% / 7.52% |
LoseABCL / S&P -156.96% / -5.03% |
| 2023-Q20/3 |
LoseABCL / S&P -14.32% / 8.74% |
LoseABCL / S&P -71.38% / 9.50% |
LoseABCL / S&P -142.86% / -8.57% |
| 2023-Q10/3 |
LoseABCL / S&P -25.57% / 7.50% |
LoseABCL / S&P -62.98% / 10.77% |
LoseABCL / S&P -128.13% / -15.69% |
| 2022-Q42/3 |
LoseABCL / S&P 2.43% / 7.56% |
WinABCL / S&P 29.37% / 11.88% |
WinABCL / S&P 6.38% / -17.99% |
| 2022-Q32/3 |
LoseABCL / S&P -7.14% / -4.88% |
WinABCL / S&P 35.92% / 13.47% |
WinABCL / S&P 9.72% / -1.41% |
| 2022-Q21/3 |
WinABCL / S&P 9.23% / -16.10% |
LoseABCL / S&P 13.33% / 13.71% |
LoseABCL / S&P -19.23% / 11.04% |
| 2022-Q10/3 |
LoseABCL / S&P -31.82% / -4.60% |
LoseABCL / S&P 13.41% / 15.97% |
LoseABCL / S&P -21.95% / 42.23% |
| 2021-Q41/3 |
LoseABCL / S&P -28.64% / 11.03% |
WinABCL / S&P 60.93% / 15.00% |
LoseABCL / S&P 6.82% / 96.40% |
| 2021-Q30/3 |
LoseABCL / S&P -8.91% / 0.58% |
LoseABCL / S&P ABCL unavailable / 10.77% |
LoseABCL / S&P ABCL unavailable / 69.42% |
| 2021-Q20/3 |
LoseABCL / S&P -35.22% / 8.55% |
LoseABCL / S&P ABCL unavailable / 6.58% |
LoseABCL / S&P ABCL unavailable / 51.81% |
| 2021-Q10/3 |
LoseABCL / S&P -15.61% / 6.17% |
LoseABCL / S&P ABCL unavailable / -1.06% |
LoseABCL / S&P ABCL unavailable / 7.39% |
| 2020-Q40/3 |
LoseABCL / S&P ABCL unavailable / 12.15% |
LoseABCL / S&P ABCL unavailable / -3.72% |
LoseABCL / S&P ABCL unavailable / -33.42% |
| 2020-Q30/3 |
LoseABCL / S&P ABCL unavailable / 8.93% |
LoseABCL / S&P ABCL unavailable / -2.04% |
LoseABCL / S&P ABCL unavailable / -27.10% |
| 2020-Q20/3 |
LoseABCL / S&P ABCL unavailable / 20.54% |
LoseABCL / S&P ABCL unavailable / -0.46% |
LoseABCL / S&P ABCL unavailable / -27.11% |
| 2020-Q10/3 |
LoseABCL / S&P ABCL unavailable / -19.60% |
LoseABCL / S&P ABCL unavailable / 3.47% |
LoseABCL / S&P ABCL unavailable / -14.75% |
| 2019-Q40/3 |
LoseABCL / S&P ABCL unavailable / 9.07% |
LoseABCL / S&P ABCL unavailable / 5.36% |
LoseABCL / S&P ABCL unavailable / 2.99% |
| 2019-Q30/3 |
LoseABCL / S&P ABCL unavailable / 1.70% |
LoseABCL / S&P ABCL unavailable / 5.02% |
LoseABCL / S&P ABCL unavailable / 0.21% |
| 2019-Q20/3 |
LoseABCL / S&P ABCL unavailable / 4.30% |
LoseABCL / S&P ABCL unavailable / 6.64% |
LoseABCL / S&P ABCL unavailable / 8.65% |
| 2019-Q10/3 |
LoseABCL / S&P ABCL unavailable / 13.65% |
LoseABCL / S&P ABCL unavailable / 8.12% |
LoseABCL / S&P ABCL unavailable / 14.29% |
| 2018-Q40/3 |
LoseABCL / S&P ABCL unavailable / -13.52% |
LoseABCL / S&P ABCL unavailable / 9.05% |
LoseABCL / S&P ABCL unavailable / 18.23% |
| 2018-Q30/3 |
LoseABCL / S&P ABCL unavailable / 7.71% |
LoseABCL / S&P ABCL unavailable / 10.21% |
LoseABCL / S&P ABCL unavailable / 19.06% |
| 2018-Q20/3 |
LoseABCL / S&P ABCL unavailable / 3.43% |
LoseABCL / S&P ABCL unavailable / 9.03% |
LoseABCL / S&P ABCL unavailable / 14.46% |
| 2018-Q10/3 |
LoseABCL / S&P ABCL unavailable / -0.76% |
LoseABCL / S&P ABCL unavailable / 7.68% |
LoseABCL / S&P ABCL unavailable / 12.46% |
| 2017-Q40/3 |
LoseABCL / S&P ABCL unavailable / 6.64% |
LoseABCL / S&P ABCL unavailable / 7.03% |
LoseABCL / S&P ABCL unavailable / 13.82% |
| 2017-Q30/3 |
LoseABCL / S&P ABCL unavailable / 4.48% |
LoseABCL / S&P ABCL unavailable / 5.68% |
LoseABCL / S&P ABCL unavailable / 17.57% |
| 2017-Q20/3 |
LoseABCL / S&P ABCL unavailable / 3.09% |
LoseABCL / S&P ABCL unavailable / 4.83% |
LoseABCL / S&P ABCL unavailable / 17.74% |
| 2017-Q10/3 |
LoseABCL / S&P ABCL unavailable / 6.07% |
LoseABCL / S&P ABCL unavailable / 3.67% |
LoseABCL / S&P ABCL unavailable / 13.32% |
| 2016-Q40/3 |
LoseABCL / S&P ABCL unavailable / 3.82% |
LoseABCL / S&P ABCL unavailable / 2.09% |
LoseABCL / S&P ABCL unavailable / 7.05% |
| 2016-Q30/3 |
LoseABCL / S&P ABCL unavailable / 3.85% |
LoseABCL / S&P ABCL unavailable / 0.20% |
LoseABCL / S&P ABCL unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ABCL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 196.65% | 20.78% |
| Annualized return | 196.65% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ABCL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -26.76% | 83.14% |
| Annualized return | -6.04% | 12.86% |
10Y · 2020-12-11 to 2026-08-27
| Metric | ABCL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -78.95% | 319.30% |
| Annualized return | -14.43% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |